ReSearch Pharmaceutical Services Inc., a Fort Washington, Penn.-based provider of clinical development services to the biopharmaceutical industry, has filed for a $100 million IPO. It plans to trade on the Nasdaq, with Jefferies & Co. serving as lead underwriter.
The company reports around $224 million in 2009 revenue, up from $175 million in 2008. Its 2009 net income was $2.6 million.
ReSearch Pharma shareholders include Cartesian Capital, The Argentum Group and First Analysis. www.rpsweb.com